How Long Does Tirzepatide Stay in Your System?

Summary: Tirzepatide's half-life is roughly 5 days, so 25 days (five half-lives) after your last injection the drug is functionally gone, though appetite, glucose, and gastric emptying effects taper across that month.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: tirzepatide has a half-life of about 5 days, and it is essentially cleared from your body in roughly 25 days, which is five half-lives, after your last injection ^[1][2][4]. That is the textbook number behind every other answer on this page. Steady state takes about four to five weeks of weekly dosing. Washout takes about four to five weeks of nothing. The drug runs on a slow, predictable clock, and almost every practical question about surgery, pregnancy, missed doses, or stopping treatment is downstream of that one number.

Here is what that means in real terms.

The pharmacokinetics, in plain numbers

Tirzepatide is engineered for slow absorption and slow elimination. The molecule is a 39-amino-acid peptide attached to a C20 fatty diacid moiety that binds reversibly to serum albumin. That albumin tethering is what keeps it in circulation for days instead of minutes. The published mean elimination half-life is approximately 116 to 120 hours, or about 5 days, in healthy volunteers and in patients with type 2 diabetes ^[1][3].

Peak plasma concentration after a subcutaneous injection occurs at roughly 24 to 72 hours post-dose. Bioavailability is about 80%. The drug is metabolized primarily through proteolytic cleavage of the peptide backbone, beta-oxidation of the fatty acid tail, and amide hydrolysis. It is not cleared appreciably by the cytochrome P450 enzymes that handle most small-molecule drugs, which is why tirzepatide has no clinically important interactions with the typical CYP-metabolized prescriptions ^[1].

The math is the same math you use for any drug. After one half-life, 50% remains. After two, 25%. After three, 12.5%. After four, 6.25%. After five half-lives, about 3% of the dose is left in circulation, which is the standard pharmacology threshold for calling a drug cleared ^[4]. Five half-lives at 5 days each is 25 days. That is where the "about a month" figure you see everywhere comes from.

Why weekly dosing works: steady state by week four to five

A 5-day half-life is the entire reason tirzepatide is a once-weekly injection. The dosing interval (7 days) is close enough to the half-life (5 days) that plasma levels never crash between doses. You get a peak in the first 1 to 3 days after the shot, a slow decline, and then the next dose lands while a meaningful fraction of last week's dose is still in circulation. The doses stack.

Stacking continues until input equals output. That is steady state, and for tirzepatide it arrives at roughly week four to week five of consistent weekly dosing at a given strength ^[1]. Average plasma concentration at steady state is about twice the average concentration after a single dose. This is why the FDA label calls for a 4-week wait at each titration step before stepping up. You are not waiting for your body to "get used to" the dose in a vague way. You are waiting for the chemistry to equilibrate so you know what the new dose actually feels like.

The same logic is why your first 2.5 mg injection feels different from your fourth. By week four you are getting the effect of the dose plus accumulated drug from the previous three weeks. If you step up to 5 mg in week five, the steady-state countdown restarts and another four weeks pass before that dose is fully expressed in your system.

Week-by-week washout after stopping

Here is what the clearance curve looks like if you take your last dose on day zero and never inject again.

That is the timeline for any reason you stop: out of supply, switching to semaglutide, taking a break, pregnancy planning, or quitting for good. The drug does not "wear off" in a single moment. It tapers across roughly four weeks, which is why many people on tirzepatide say they did not realize they had stopped until their hunger came back in week two or three.

Two things to plan for during the washout:

• Appetite rebound. The appetite suppression is dose-proportional. As plasma levels drop, hunger and cravings return on roughly the same curve as the drug clearance. Most people feel a noticeable shift around days 10 to 14 ^[4].
• Glycemic loosening. If you were on tirzepatide for type 2 diabetes, blood sugar control will start drifting upward as the drug clears. This is the most important reason to never stop tirzepatide for diabetes without a transition plan from your prescriber.

Surgery and anesthesia: hold one to two weeks pre-op

GLP-1 receptor agonists slow gastric emptying. Tirzepatide, with its dual GIP/GLP-1 mechanism, slows it significantly in the first weeks of therapy, with the effect attenuating over time as tachyphylaxis develops ^[3]. The clinical worry is regurgitation and pulmonary aspiration during induction of anesthesia, because a "fasted" stomach on a GLP-1 drug may still contain solid food many hours after the last meal.

The American Society of Anesthesiologists issued consensus guidance in 2023 and refined it in 2024 recommending that patients on weekly GLP-1 receptor agonists, including tirzepatide, hold the medication for at least one week before an elective procedure requiring sedation or general anesthesia ^[5]. Many surgical teams ask for a longer pause, typically one to two weeks, given tirzepatide's 5-day half-life and the fact that even at two weeks roughly a quarter of the last dose is still on board.

Practical playbook for elective surgery:

Emergency surgery is different. You cannot hold a drug for two weeks if you need an appendectomy today. In that case the anesthesia team will use a rapid sequence induction protocol that assumes a full stomach and protects the airway accordingly. This is why disclosing tirzepatide use is non-negotiable on intake, even in the ER.

For endoscopy and colonoscopy, gastroenterology societies have published similar guidance. Many centers now ask for a 1-week hold before upper endoscopy specifically because residual food in the stomach blocks visualization and forces a repeat procedure.

Pregnancy: stop one month before conception

Tirzepatide is not recommended in pregnancy. Animal reproductive studies showed fetal growth reductions and developmental abnormalities at clinically relevant exposures, and there is no controlled human pregnancy data ^[1][2]. The FDA label for both Mounjaro and Zepbound advises discontinuing tirzepatide when pregnancy is recognized and switching to an alternative treatment for diabetes if needed.

The practical timeline for anyone planning a pregnancy:

• Stop tirzepatide at least one month (roughly 4 to 5 half-lives) before trying to conceive. This matches the standard washout window where the drug is functionally cleared. Some clinicians recommend two months for extra margin, particularly given the long terminal elimination tail.
• Use reliable contraception during the washout period. Tirzepatide may also reduce the effectiveness of oral contraceptives during the four weeks after starting therapy or increasing the dose, because slowed gastric emptying affects pill absorption ^[1]. The FDA label specifically recommends barrier contraception or switching to a non-oral method for four weeks after starting Mounjaro and after each dose escalation.
• Discuss the diabetes or weight-management plan with your obstetric and primary teams before stopping. Glycemic control during pregnancy matters, and a switch to insulin or another pregnancy-compatible regimen may be needed in advance.

Tirzepatide is also not recommended while breastfeeding because of the absence of safety data in nursing infants.

What happens if you miss a dose

Because the half-life is 5 days, missing one weekly dose does not crash your plasma levels. You have a wide forgiveness window. The FDA prescribing information gives clear guidance ^[1][2]:

• If the missed dose is within 4 days (96 hours) of the scheduled day, take it as soon as you remember and continue your normal weekly schedule.
• If more than 4 days have passed, skip the missed dose and take the next one on your regular day. Do not double up.

The reason the 4-day cutoff exists is that taking a dose more than 4 days late starts to push the next scheduled dose closer than the minimum 3-day spacing the manufacturer validated for safety. Doubling up is never the answer, because tirzepatide side effects are dose-dependent and the GI effects of a double dose are harsh.

If you miss multiple weekly doses in a row, you may need to restart titration. The general rule is that if you have not injected for more than 4 weeks, your steady-state plasma concentration has dropped substantially, and resuming at a high dose can produce the nausea and vomiting you experienced the first time you escalated. Talk to your prescriber about whether to step back to a lower dose and re-titrate.

Factors that change your personal clearance time

The 5-day half-life is a population average. Your individual clearance can vary, though usually not by much.

• Renal function. Tirzepatide does not require a dose adjustment in mild, moderate, severe, or end-stage renal disease, including dialysis ^[1]. Pharmacokinetic studies show only modest changes in exposure across renal function categories. Renal impairment does not meaningfully extend the clearance window for most patients.
• Hepatic function. Similarly, no dose adjustment is needed in hepatic impairment, and the elimination timeline is essentially unchanged ^[1].
• Age. Adults over 65 may clear the drug slightly more slowly, but the difference is small enough that no age-based dosing adjustment is recommended.
• Body weight. Tirzepatide exposure is dose-proportional and only modestly affected by body weight. Heavier patients do not need higher doses to achieve target plasma levels.
• Dose. Higher doses take marginally longer to clear to undetectable, because you are starting from a higher peak. The half-life itself does not change with dose; the number of days to reach a threshold concentration scales with the log of the starting concentration. In practice, the difference between clearing a 2.5 mg dose and a 15 mg dose is days, not weeks.

There is no validated test you can take at home or at a routine lab to measure tirzepatide plasma concentration. Specialty bioanalytical labs can quantify it, but that is research and forensic use, not clinical care.

Effects can outlast detectable drug

Plasma clearance is not the same as biological effect clearance. Even after tirzepatide is essentially gone from your bloodstream around day 25 to 30, some downstream effects can persist:

• Gastric emptying typically normalizes within the same washout window, with most patients returning to baseline within 4 to 6 weeks.
• Glycemic improvement can persist for several weeks beyond drug clearance in patients whose insulin sensitivity has improved during therapy. The effect fades as insulin resistance creeps back if lifestyle and weight changes are not maintained.
• Weight maintenance is the most variable. The drug's pharmacological appetite suppression is gone within a month, but body-composition changes, food habits, and metabolic adaptations from the treatment period can support continued weight stability for some people and rapid regain for others. The SURMOUNT-4 trial showed that participants who switched from tirzepatide to placebo regained about half of their lost weight within a year, which is the population-level reality of stopping.

How tirzepatide compares to other GLP-1 drugs in your system

Semaglutide stays in the system slightly longer than tirzepatide because of its 7-day half-life, which is why surgical hold recommendations are similar between the two but semaglutide guidance sometimes asks for two weeks. Liraglutide, on the other hand, clears in days because of its much shorter half-life, which is why daily dosing is required and why the pre-op hold is much shorter.

Storage and shelf life: separate from clearance, but related

A common follow-up question is how long tirzepatide lasts outside your body, not inside it. The storage rules are short. The FDA label for both Mounjaro and Zepbound specifies refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) ^[1][2]. Do not freeze; freezing breaks down the peptide and the dose should be discarded if it ever froze. If a pen or vial got warm because you left it out, the labeling allows for storage at room temperature up to 86 degrees Fahrenheit (30 degrees Celsius) for up to 21 days. After 21 days at room temperature, discard.

Compounded tirzepatide may have different beyond-use dates depending on the pharmacy, typically 28 to 56 days after first puncture for multi-dose vials. The pharmacy label is the only authoritative source for compounded shelf life. Brand pens have a stamped expiration date that applies to refrigerated storage.

If you accidentally left a brand pen out overnight at typical indoor temperatures, it is fine to use as long as the cumulative time at room temperature is under 21 days and the temperature stayed below 86 degrees. If a pen sat in a hot car or a sunny window, throw it out.

When to call your prescriber

A few clearance-related situations that warrant a phone call before you act:

• You are scheduled for surgery, endoscopy, or a procedure with sedation in the next two weeks.
• You are trying to conceive within the next two to three months.
• You have missed more than two consecutive weekly doses and are not sure whether to restart at the same dose.
• You are switching from tirzepatide to a different GLP-1 drug and need a transition plan that accounts for the four-week tail.
• You have persistent nausea, vomiting, or severe abdominal pain that has not resolved within a week of your last dose, particularly if you have a history of pancreatitis or gallbladder disease.

Frequently asked questions

How long does it take for tirzepatide to wear off?

Tirzepatide is functionally cleared from your system about 25 days after your last dose, which is 5 half-lives at 5 days each. Appetite usually returns within 1 to 2 weeks as plasma levels drop, with most pharmacological effects gone by week 4.

How long does it take to reach steady state on tirzepatide?

Steady-state plasma concentrations are reached after about 4 to 5 weeks of consistent weekly dosing at a given strength. This is why FDA labeling spaces each dose escalation 4 weeks apart.

Do I need to stop tirzepatide before surgery?

Yes. The American Society of Anesthesiologists recommends holding weekly GLP-1 drugs, including tirzepatide, for at least 1 week before elective procedures requiring sedation or general anesthesia. Many surgical teams ask for 1 to 2 weeks. Always disclose tirzepatide use during pre-op screening.

How long before pregnancy should I stop tirzepatide?

Stop tirzepatide at least 1 month before trying to conceive. Some clinicians recommend 2 months for additional margin. Use reliable contraception during the washout, and switch to barrier or non-oral methods for 4 weeks after starting tirzepatide or after each dose escalation since gastric emptying slows oral contraceptive absorption.

What if I miss a weekly tirzepatide dose?

If it has been 4 days or fewer, take the missed dose as soon as you remember and resume your normal schedule. If more than 4 days have passed, skip it and take the next dose on your regular day. Never double up.

How long does tirzepatide last in the fridge?

Refrigerated at 36 to 46 degrees Fahrenheit, a Mounjaro or Zepbound pen is stable through the stamped expiration date on the carton. Compounded vials are typically stable for 28 to 56 days after first puncture, but the pharmacy label is the only authoritative source for compounded shelf life.

Does tirzepatide expire after 28 days?

Brand pens (Mounjaro and Zepbound) do not expire after 28 days. They are good until the stamped expiration date if refrigerated, or for 21 days if kept at room temperature. The 28-day figure is a common compounded-vial beyond-use date but is not universal.

I accidentally left my tirzepatide out overnight. Is it still safe?

Probably yes. The FDA labeling allows storage at room temperature up to 86 degrees Fahrenheit for up to 21 days total. An overnight room-temperature exposure in a typical indoor environment falls well within that window. Discard if the pen got hot (above 86 degrees) or if it ever froze.

Can tirzepatide be frozen?

No. Freezing breaks down the peptide structure. If your tirzepatide ever froze, discard it and request a replacement. This is true for both brand pens and compounded vials.

What temperature does tirzepatide need to be stored at?

Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Room-temperature storage is acceptable up to 86 degrees Fahrenheit (30 degrees Celsius) for a maximum of 21 days, after which any unused product should be discarded.

Will tirzepatide show up on a drug test?

No. Tirzepatide is a peptide drug and is not screened for on any standard employment, athletic, or forensic drug panel. The drug panels look for small-molecule drugs of abuse, not therapeutic peptides.

How does tirzepatide clearance compare to semaglutide?

Tirzepatide has a 5-day half-life and clears in about 25 days. Semaglutide has a 7-day half-life and clears in about 5 weeks. The difference is small in clinical practice. Both require similar surgical-hold and pregnancy-planning windows.

The bottom line

Five days in, five doses to steady state, twenty-five days out. That sequence captures the entire pharmacokinetic story of tirzepatide. Plan your surgeries and pregnancies around the 25-day clearance window, escalate your dose on the 4-week steady-state clock, and use the 4-day missed-dose rule as your forgiveness window. The slow, predictable timing is what makes the drug convenient. It is also what makes the planning around it non-negotiable.